We previously demonstrated that type 2C protein phosphatases (PP2C) Ptc2 and Ptc3 are required for DNA checkpoint inactivation after DNA double-strand break repair or adaptation in Saccharomyces cerevisiae. Here, we show the conservation of this pathway in mammalian cells. In response to DNA damage, ataxia telangiectasia mutated (ATM) phosphorylates the Chk2 tumour suppressor kinase at threonine 68 (Thr68), allowing Chk2 kinase dimerization and activation by autophosphorylations in the T-loop. The oncogenic protein Wip1, a PP2C phosphatase, binds Chk2 and dephosphorylates phosphoThr68. Consequently, Wip1 opposes Chk2 activation by ATM after ionizing irradiation of cells. In HCT15 colorectal cancer cells corrected for functional Chk2 activity, Wip1 overexpression suppressed the contribution of Chk2 to the G2/M DNA damage checkpoint. These results indicate that Wip1 is one of the phosphatases regulating the activity of Chk2 in response to DNA damage.
Introduction
DNA damage activates checkpoint signalling pathways that arrest the cell cycle to provide time for DNA repair, activate DNA repair processes or induce apoptosis in the case of severe damage (Zhou and Elledge, 2000) . These events ensure genomic stability. Two protein kinases, ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3-related (ATR), play key roles in activating these signalling pathways. In response to ionizing irradiation (IR), ATM is activated within minutes at sites of DNA double-strand breaks (DSBs) (Goodarzi et al., 2004) , and allows further activation of ATR in S or G2 phase cells (Jazayeri et al., 2006) . ATR and ATM then activate, respectively, Chk1 and Chk2, which are key elements in amplifying and transducing the DNA damage signal to the entire nucleus .
Chk2 activation requires its phosphorylation by ATM at Thr68 within an amino-terminal SQ/TQ cluster Melchionna et al., 2000) . This ATM-dependent phosphorylation event might be facilitated by the Plk3-mediated phosphorylation of Chk2-Ser73 (Bahassi el et al., 2006) . Intermolecular interactions between one phospho-Thr68 Chk2 with the forkhead-associated (FHA) domain of another Chk2 molecule lead to homodimerization of the kinase and autophosphorylation at Thr383 and Thr387 within the activation loop of the catalytic domain that is required for full Chk2 activation (Xu et al., 2002; Schwarz et al., 2003) . Interestingly, Thr68 phosphorylation is not required to maintain Chk2 kinase activity after autophosphorylation of its T-loop . Additional phosphorylations of Chk2 in irradiated cells include Ser19, Thr26, Ser28/33, Thr432 and Ser516 (Schwarz et al., 2003; Ahn et al., 2004) . Chk2 phosphorylates multiple substrates including the Brca1 protein to promote DNA repair, p53, CDC25A, CDC25C and Plk3 to inhibit cell cycle progression in the G1, S and G2 phases of the cell cycle, and p53, PML and E2F-1 to stimulate apoptosis . A recently released Chk2 molecular map (http:// discover.nci.nih.gov/mim) summarizes all known Chk2 interactions (Pommier et al., 2006) . In cycling cells, most Chk2 substrates involved in cell cycle control are also substrates of Chk1, so there is considerable functional overlap between these two kinases . However, Chk1 is activated primarily by ATR in response to replicative stress whereas Chk2 is activated principally by ATM in response to DNA DSBs.
The multiple roles of Chk2 in contributing to genome stability suggested that it would be an important tumour suppressor. Indeed, Chk2 mutations have been found in variant forms of the Li-Fraumeni syndrome as well as in lymphoma, sarcoma and carcinoma of the breast, ovary, lung and colon (Craig and Hupp, 2004) . Chk2 inactivation in tumours could potentially occur through downregulation of its kinase activity. Chk2 dephosphorylation and/or degradation could theoretically be involved in this process. Rad53 is the budding yeast ortholog of Chk2. Previously, we showed that two type 2C protein phosphatases (PP2C), Ptc2 and Ptc3, were required for inactivation of the Rad53 DNA damage checkpoint during adaptation and recovery from a DNA DSB in Saccharomyces cerevisiae (Leroy et al., 2003) . In this study, we sought to test the conservation of this pathway by looking for an orthologous human PP2C phosphatase able to inactivate Chk2.
PP2C phosphatases are monomeric, Mg 2 þ -dependent Ser/Thr phosphatases that have been implicated in stress response signalling pathways (Schweighofer et al., 2004) . The mammalian PPM1D gene coding for the nuclear PP2C delta isoform (or Wip1) was originally identified by its p53-dependent transcriptional induction in response to ionizing IR (Fiscella et al., 1997) and was thus of particular interest for further study. Mice deficient for Wip1 exhibit defects in reproductive organ and immune function, and Wip1 À/À MEF cells have decreased proliferation rates owing to the activation of the p16 (Ink4a) and p19 (ARF) pathways (Choi et al., 2002; Bulavin et al., 2004) . In response to genotoxic stress, Wip1 was recently shown to downregulate several checkpoint pathways. First, Wip1 binds and dephosphorylates UV-activated p38 MAP kinase, inhibiting p38 activity and preventing p53 stabilization (Takekawa et al., 2000) . Second, Wip1 dephosphorylates p53 at phospho-Ser15, which is targeted by the ATM/ATR kinases (Lu et al., 2005) . Third, Wip1 directly inhibits Chk1 by dephosphorylating the ATR-targeted phosphoSer345 (Lu et al., 2005) . In addition, Wip1 directly dephosphorylates and inhibits a uracil N-glycosylase (Ung2) implicated in the base excision repair of DNA (Lu et al., 2004) . The overexpression of Wip1 is likely to be oncogenic given its antagonism of key proteins involved in maintaining genomic stability. Indeed, the Wip1 gene at human chromosome 17q23 is amplified in 15% of human breast cancers, and its overexpression is found in an aggressive subset of breast, prostate, ovarian and brain cancers of poor prognosis (Hirasawa et al., 2003; Saito-Ohara et al., 2003; Sinclair et al., 2003) .
In this study, we show that Wip1 dephosphorylates Chk2 phospho-Thr68 and thereby antagonizes its activation by ATM after ionizing IR of cells.
Results

Wip1 binds Chk2
To identify a human PP2C phosphatase able to downregulate Chk2 kinase activity, we started with in vitro assays to search for protein interaction using purified recombinant Chk2 and GST-PP2Cs. Among the PP2C phosphatases, Wip1 had characteristics that were most consistent with a role in downregulating the DNA damage checkpoints as explained above. We found that purified recombinant Chk2 was retained by GST-Wip1, but not by GST or by GST-PP2Ca that served as specificity controls (Figure 1a, lanes 4, 2, 12, respectively) . The interaction between the Chk2 and Wip1 proteins resisted washes in the presence of high salt concentration (800 mM, lane 6) or detergent (1% Igepal, lane 7). GST-Wip1 binding to recombinant Chk2 is therefore specific and quite strong under these in vitro conditions. These results were confirmed by pulldown assays using GST-Wip1 and cellular extracts containing overexpressed haemagglutinin-tagged Chk2 (HA-Chk2) (Figure 1a , lanes 9 and 10). Wip1 is a magnesiumdependent phosphatase. The presence of 1 mM ethylene diaminetetraacetic acid, a concentration inhibiting Wip1 phosphatase activity, almost abolished the interaction between Wip1 and Chk2 (data not shown). Thus, Wip1 interaction with Chk2 probably requires its catalytic activity or a specific conformation. Conversely, we tested whether Chk2 phosphorylation was necessary for its binding to Wip1. A high local concentration of Chk2 in the presence of ATP is sufficient for its autophosphorylation. The purified recombinant Chk2-His produced in Escherichia coli and the HA-Chk2 overexpressed in Chinese hamster ovary (CHO) cells are highly phosphorylated (Ahn and Prives, 2002; Schwarz et al., 2003) . These forms of Chk2 interact with Wip1 ( Figure 1a ). To compare binding of Wip1 to inactive, unphosphorylated Chk2 and physiologically activated Chk2, we used HCT15 cells stably expressing endogenous levels of HA-Chk2 (HCT15/HA-Chk2). These cells were X-irradiated with 8 Gy or mock-irradiated, and whole-cell extracts were incubated with exogenous GST-Wip1 before HA-Chk2 immunoprecipitation. For this experiment, we used a preparation of GST-Wip1 purified from baculovirus-infected insect cells that had fewer proteolytic products than the E. coli preparation (Figure 1a and b). Wip1 bound HA-Chk2 only in extracts from irradiated cells, suggesting that Chk2 phosphorylation upon IR was required for this interaction ( Figure 1b ).
In vitro activity and specificity of the Wip1 phosphatase towards phospho-Chk2
Having established that Wip1 binds phospho-Chk2, we next analysed the Wip1 phosphatase activity and specificity towards Chk2 phosphorylation sites. First, the activities of GST-Wip1 (from insect cells) and GSTPP2Ca (from E. coli) were calibrated using a nonspecific substrate, casein, that had been phosphorylated by protein kinase A (PKA) or the p38 MAP kinase in the presence of (g-32 P)ATP. 1.4 mg (0.2 mM) of GST-Wip1 displayed the same activity as 2.2 mg (0.45 mM) of GSTPP2Ca in dephosphorylating casein previously phosphorylated by PKA (Figure 2a , left panel). However, PP2Ca was more active than GST-Wip1 towards casein phosphorylated by p38 when the same quantities of the two phosphatases were compared (Figure 2a , right panel). In contrast, using autophosphorylated Chk2 as substrate, GST-Wip1 eliminated up to 50% of the incorporated radioactivity, whereas PP2Ca had only a minor phosphatase activity (around 15% after a 2 h reaction; data not shown). This suggested that Wip1 displayed some phosphatase activity on a subset of Chk2 phosphorylated sites, whereas PP2Ca targeted only some of them or displayed only a minor global phosphatase activity. This point was addressed using cellular extracts of CHO cells overexpressing Chk2. The autophosphorylated Chk2 in the extract was incubated in the presence of various amounts of phosphatases (the ratio between the quantities of GST-Wip1 and GSTPP2Ca was maintained at 1.6 as determined in the calibration experiment) and we determined the phosphorylation status of Chk2 at different Ser/Thr residues during a short time course (Figure 2b ). Strikingly, dephosphorylation of Chk2 at Thr68 occurred very quickly in the presence of as little as 10 ng (4 nM) of GST-Wip1, whereas 800 ng (500 nM) of GST-PP2Ca or 8 U of calf intestinal phosphatase (CIP) were ineffective. None of the three tested phosphates displayed any activity on the phospho-Thr387 activation loop site. Phospho-Ser19 was efficiently dephosphorylated by PP2Ca and CIP, but relatively poorly by Wip1. Phospho-Ser33 was dephosphorylated only by large quantities of Wip1 and CIP. Phospho-Thr432 was dephosphorylated by large amounts of PP2Ca and by CIP, but not efficiently by Wip1. Finally, phosphoSer516 was readily dephosphorylated by all three phosphatases, suggesting that it is freely accessible to phosphatase action. In conclusion, Wip1 is unique among these three phosphatases in efficiently dephosphorylating phospho-Thr68. Other sites are readily dephosphorylated by all three phosphatases (pS516) or are only dephosphorylated at much higher concentrations of Wip1 (pS33). Interestingly, phospho-Thr387 in the activating T-loop was not targeted by Wip1, suggesting that a fully active Chk2 might be insensitive to the Wip1 phosphatase.
We thus tested the effect of Wip1 treatment on Chk2 kinase activity. Extracts from CHO cells overexpressing HA-Chk2 were treated with varying amounts of GSTWip1 and HA-Chk2 was subsequently immunoprecipitated. The immunoprecipitated HA-Chk2 kinase activity was then assayed using a GST-Cdc25C fusion protein as substrate. A typical dose-response curve and the means and standard errors for the 10 and 100 ng experiments are shown in Figure 2c . The lowest quantity of Wip1, 10 ng (1 nM), reduced Thr68 phosphorylation to 36.877.1% (n ¼ 4) whereas the kinase activity was unchanged (98.877.6%). Higher quantities of Wip1, 50-500 ng (5-50 nM), led to an almost complete dephosphorylation on Thr68, the residual signal being stable around 10% (11.273.5% for 100 ng, n ¼ 5). However, under these conditions, the kinase activity was significantly inhibited (residual activity at 51.478.5%). We verified that Wip1 has no phosphatase activity upon phosphorylated GST-Cdc25C (not shown and (Lu et al., 2005) ). As the phosphorylation state of Thr387 was unchanged (data not shown), the inhibition of Chk2 kinase activity in the presence of large amounts of Wip1 suggests either that additional dephosphorylations of Chk2 occur in these conditions (e.g., on Thr383 of the activation loop), or that a direct binding by Wip1 might change the accessibility of the Chk2 catalytic site.
From these in vitro studies, we conclude that, first, Wip1 displays a specific phosphatase activity on phospho-Thr68 of Chk2; second, Chk2 kinase activity is not modified by low levels of Wip1; and third, large amounts of Wip1 can reduce the Chk2 kinase activity to half of its control value.
In vivo biochemical consequences of Wip1 and Chk2 interactions The effect of Wip1 expression on Chk2 phosphorylation and Chk2 activity was then tested in cellular models. In CHO cells, the transfection of a plasmid expressing Chk2 from the cytomegalovirus (CMV) promoter led to Chk2 autophosphorylation on Thr68 and Thr387 ( Figure 3a) . The co-transfection with a pCMV-Wip1 expression plasmid dramatically reduced the autophosphorylation on Thr68, whereas there was little effect on Thr387 phosphorylation (Figure 3a) . Moreover, under these conditions of high-level Chk2 expression, high levels of Thr68 phosphorylation are not required for autophosphorylation of Chk2 on its activation loop.
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We then examined a cellular model in which Chk2 would be activated only in response to a genotoxic stress such as ionizing radiation. The HCT15 colorectal cancer cell line exhibits neither functional Chk2 nor functional p53 (Falck et al., 2001) . The absence of functional Chk2 is due to mutations in the two alleles: one allele bears the A247D mutation in the conserved catalytic motif and is not expressed (Lee et al., 2001) , and the second allele codes for a R145W mutant protein. This protein is not as stable as the wild type, cannot be activated by ATM because of the mutation in the FHA domain and does not exhibit a dominantnegative effect in the presence of a wild-type Chk2 (Lee et al., 2001; Wu et al., 2001) . We therefore used HCT15 cells and HCT15 cells expressing an endogenous level of functional HA-Chk2 (HCT15/HA-Chk2 cells) that were Phosphorylation at Thr68, Thr387, Ser19, Ser33, Thr432 and Ser516 was monitored by Western blotting using specific anti-phospho-Chk2 antibodies. Anti-HA immunoblotting served as a loading control. (c) CHO cells transiently expressing HA-Chk2 were harvested 24 h post-transfection. Forty micrograms of WCLs were treated 30 min at 301C by the indicated amounts of GST-Wip1. HA-Chk2 was then immunoprecipitated and its kinase activity was measured on a PhosphorImager following 32 P incorporation on GST-Cdc25C. Phosphorylation on Thr68 was monitored by Western blotting (the films were scanned and then analysed by Image Quant software, Saclay, France).
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M Oliva-Trastoy et al generously provided by Dr J Chen (Wu and Chen, 2003) . In exponentially growing HCT15/HA-Chk2 cells, the Chk2 kinase is not activated, as seen by the absence of Thr68 phosphorylation. Upon 8 Gy of X-IR, Chk2 was phosphorylated on Thr68 within minutes whereas Wip1 levels remained low in the absence of p53 (Figure 3b ). The peak of Thr68 phosphorylation was reached 20-60 min after IR (Figure 3b ). Eight hours after IR, Thr68 phosphorylation was still about one-third of its maximum. When these cells were nucleofected with a pCMV-Wip1 construct instead of a control vector, the phosphorylation of Chk2 at Thr68 was reduced. Moreover, as we observed the same results when Wip1 was expressed from the weak EF1a promoter (Figure 3c ), a modest level of Wip1 overexpression is sufficient to reduce Thr68 Chk2 phosphorylation. In addition, phospho-Thr68 dephosphorylation required Wip1 catalytic activity as we observed no effect with the expression of a Wip1 phosphatase-dead mutant (D314A; Figure 3c ). Conversely, the nucleofection of small interfering RNA (siRNA) to Wip1 led to increased phosphorylation of Chk2 on Thr68 (Figures 3b and c) , suggesting that only a fraction of Chk2 (at most 2/3 upon 8 Gy of IR) is phosphorylated on Thr68 upon IR. Thus, in HCT15/HA-Chk2 cells, the phospho-Thr68 level results from a dynamic equilibrium between ATM phosphorylation and Wip1 dephosphorylation.
Ex vivo Chk2 kinase activity was measured using extracts from HCT15/HA-Chk2 cells. After IR of cells nucleofected with a control plasmid, the activity of immunoprecipitated HA-Chk2 kinase on a GSTCdc25C substrate increased, reached a maximum at about 1 h and then decreased (Figure 3d ). This time course of Chk2 activity follows that of Thr68 phosphorylation (Figure 3c ). The cells that overexpressed Wip1 also displayed an increased Chk2 activity, but this increase was delayed, the maximum of activity being observed about 3 h after IR. These results suggest that Wip1 inhibition of Thr68 phosphorylation delays Chk2 oligomerization, slowing then T loop autophosphorylation and deferring kinase activity. Altogether, these results led us to conclude that Wip1 inhibits Chk2 activation in response to a genotoxic stress.
Effects of Wip1 overexpression on the G2 cell cycle checkpoints
We examined the consequences of modifying Wip1 levels on the cell cycle of HCT15 and HCT15/HA-Chk2 cells subjected to 8 Gy of X-IR. This model has several advantages. First, the lack of functional p53 eliminates the predominant p21-mediated G1 checkpoint response and allows us to focus on G2 checkpoints that involve Chk1 and Chk2. The absence of p53 also leads to a Wip1 phosphatase antagonizes Chk2 activation M Oliva-Trastoy et al constant, basal level of endogenous Wip1 expression that allows a more controlled monitoring of Wip1 levels (Figure 3b) . Second, we verified that, upon X-IR, there was no activation of p38 MAP kinase, another known target of Wip1 (data not shown). Finally, the use of isogenic cells differing only in their Chk2 status allowed us to specifically evaluate the effect of Wip1 on Chk2 by comparing the response of each cell line to changes in Wip1 levels.
We treated asynchronous HCT15 and HCT15/ HA-Chk2 cells with 8 Gy of X-IR and we observed an accumulation of cells in the G2 phase of the cell cycle up to about 21 h post-IR, followed by their exit from the G2 arrest. The irradiated HCT15 cells were recovered from the G2 arrest 2 h earlier than the HCT15/ HA-Chk2 cells (Figure 4 ). This additional 2 h delay in G2 phase arrest is thus because of the presence of functional Chk2. It was clear that the HCT15 parental cell line that did not express functional Chk2 nevertheless had a robust accumulation in G2 in response to X-IR. We thus used Chk1 siRNAs to evaluate the relative importance of Chk1 to the G2 arrest of irradiated HCT15 cells. Strikingly, knock down of Chk1 allowed the irradiated HCT15 cells to recover from G2 arrest about 12 h earlier than the control cells (Figure 4 ). These observations are consistent with results in other cell lines suggesting that Chk1 has a major role in determining the G2 arrest in response to ionizing IR in mammalian cells, with Chk2 having a modulating role on the length of the delay (Hirao et al., 2000; Xiao et al., 2003) .
Upon transfection with pCMV-Wip1, G2 exit is advanced modestly in the HCT15 cells, but more significantly in the HCT15/HA-Chk2 cells such that they exited G2 at the same time as the parental HCT15 cells (Figure 4 ). This result is consistent with Wip1 suppressing the contribution of Chk2 to the G2 arrest of the HCT15/HA-Chk2 cells.
Discussion
Wip1 selectively reverses the action of ATM on Chk2
We previously showed that the Ptc2 and Ptc3 phosphatases in budding yeast interact with and downregulate the Rad53 checkpoint kinase after a DNA DSB (Leroy et al., 2003) . Ptc2 and Ptc3 belong to the PP2C family of protein phosphatases. In seeking to test the conservation of this pathway in mammalian cells, we found that the PP2C phosphatase Wip1 binds Chk2, the mammalian ortholog of Rad53. Interestingly, this interaction was stimulated in cells subjected to ionizing IR, suggesting that modification of Chk2 after IR may be required for the interaction. One possibility is that phosphorylation of Chk2, induced by the ionizing IR, is required to form a high-affinity binding site for Wip1.
Wip1 dephosphorylates phospho-Thr68 of Chk2 with great efficiency under conditions in which the closely related PP2Ca phosphatase or the CIP is ineffective. It also dephosphorylates phospho-Ser516 efficiently, but PP2Ca and CIP do so as well, suggesting that this site is highly accessible and easily dephosphorylated. Wip1 also dephosphorylates phospho-Ser33, but much less efficiently than phospho-Thr68. All of the phosphoChk2 sites dephosphorylated by Wip1 have the common sequence S/TQ that is phosphorylated by the ATM/ ATR kinases. Recently, Donehower and colleagues showed that Wip1 could also dephosphorylate phospho-Chk1 on the ATR-phosphorylated S345Q and p53 on the ATM/ATR phosphorylated S15Q, which suggests that Wip1 can generally dephosphorylate S/TQ sites (Lu et al., 2005) . However, Wip1 shows a great variability in activity towards phospho-S/TQ sites. We found that it dephosphorylates Chk2 on pS33Q much less efficiently than pT68Q, and pT432Q was largely resistant to its action. Moreover, we failed to see an effect of Wip1 overexpression on ATM phosphorylation of Nbs1 on pS343Q (data not shown). These results indicate that Wip1 does not act as a phosphatase uniformly reversing the action of the ATM/ATR kinases. Rather, it appears to selectively dephosphorylate some key sites with high efficiency, such as at phospho-Thr68 of Chk2. 
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Wip1 also dephosphorylates p38 and UNG2 at pT180GY and pT6LY sites, respectively (Takekawa et al., 2000; Lu et al., 2004) . In the case of the p38 MAP kinase, the TGY motif is part of the activation loop of the kinase and is diphosphorylated on Thr and Tyr residues when p38 is activated. Using model peptide substrates, Appella and colleagues found that Wip1 had a 6-8-fold higher catalytic efficiency for a diphosphorylated pTXpY substrate compared to the same peptide mono-phosphorylated on threonine (Yamaguchi et al., 2005) . This observation suggests that a negatively charged residue at position T þ 2 may increase the affinity of Wip1 for its substrate, which may explain why Wip1 targets pT68QE of Chk2 so efficiently.
Wip1 inhibits Chk2 activation in X-irradiated cells
PP2Ca and Wip1 inactivate Cdk1 and the p38 MAP kinase, respectively, by dephosphorylating phospho-Thr residues in their activation loops. Given these precedents, we initially assumed that Wip1 would similarly inactivate Chk2 by dephosphorylating phospho-Thr383 and/or phospho-Thr387 in its activation loop. However, our data clearly show that phospho-Thr387 is highly resistant to Wip1 action under conditions in which phospho-Thr68 is readily dephosphorylated. There are no antibodies available to probe the phosphorylation status of Thr383, but a dose-response analysis of the effect of Wip1 on activated Chk2 showed that low levels of Wip1 removed Thr68 phosphorylation without affecting Chk2 catalytic activity. These observations are consistent with data showing that ATM phosphorylation of Thr68 is vital for Chk2 activation in allowing dimerization and Chk2 autophosphorylation on its T-loop, but is not required to maintain Chk2 kinase activity Ahn and Prives, 2002; Schwarz et al., 2003) . At 10-fold higher levels of Wip1, we found an approximately 50% inhibition of Chk2 kinase activity. At these high levels, Wip1 may inhibit Chk2 by dephosphorylating non-preferential sites that contribute to Chk2 kinase activity. We did not observe any change in Thr387 phosphorylation status under these conditions, but we cannot exclude an effect on phospho-Thr383. High levels of Wip1 might also inhibit Chk2 by binding in such a way as to induce an unfavourable conformation or sterically hinder the active site of Chk2.
While this manuscript was in preparation, Fujimoto et al. (2005) published results similar to ours regarding the binding of Wip1 to Chk2 and the dephosphorylation of phospho-Thr68 . However, there are key differences in some of our results and interpretations. Fujimoto et al. (2005) did not determine whether or not IR stimulates the interaction of Wip1 and Chk2 within cells as we did. They also did not report dose-response analyses that allowed us to distinguish the increased catalytic efficiency and specificity of Wip1 towards phospho-Thr68 compared with the other Chk2 phosphorylation sites. Finally, they did not find phosphoSer516 to be a substrate for Wip1, whereas we found that it is readily dephosphorylated by Wip1, PP2Ca and CIP in vitro. We do not know the basis for these discrepancies, but it has some import in that Fujimoto et al. (2005) . showed that Wip1 antagonizes Chk2-dependent apoptosis of g-irradiated MCF7 breast cancer cells, and Chen and colleagues previously established, in the HCT15 cell line, a role for Chk2 Ser516 phosphorylation in stimulating Chk2-dependent apoptosis (Wu and Chen, 2003) . Thus, Wip1 dephosphorylation of Ser516 may be important in mediating this antiapoptotic effect. Fujimoto et al. (2005) also found that the addition of a large excess of GST-Wip1 (1 mg) to preactivated Chk2 led to phospho-Thr68 dephosphorylation and a 50% inhibition of Chk2 kinase activity towards a GSTCdc25C substrate. They concluded that Wip1 treatment resulted in a 'drastic inhibition of Chk2 kinase activity [y] in vitro' and they suggested that this effect might be important for Chk2 inhibition by Wip1 in vivo (Fujimoto et al., 2005) . We also observed a partial inhibition of preactivated Chk2 kinase activity in vitro upon the addition of large quantities of Wip1 (100-500 ng). However, our dose-response curve indicated that lower, more physiological levels of Wip1 (10 ng) could effectively dephosphorylate phospho-Thr68 without affecting the catalytic efficiency of the preactivated Chk2. We thus feel that under physiological conditions, Wip1 regulates the rate at which Chk2 can be activated by ATM through its antagonism of Thr68 phosphorylation, but that it cannot appreciably reverse the activity of Chk2 after its autophosphorylation on the T-loop. We suggest that the suppression of preactivated Chk2 kinase activity requires other unidentified phosphatases that specifically target phospho-Thr383 and phosphoThr387 residues of the T-loop. Our extensive time course analyses of Chk2 activation by X-IR of HCT15/ HA-Chk2 cells in conditions of increased and decreased Wip1 phosphatase levels support this model. Increased expression of Wip1 in these cells led to a greatly delayed accumulation of phospho-Thr68 and Chk2 kinase activation after X-IR. Conversely, siRNA knock down of endogenous Wip1 led to sustained hyperphosphorylation of Thr68. Wip1 thus antagonizes activation of Chk2 by ATM in response to ionizing IR by its efficient dephosphorylation of phospho-Thr68.
Recently, protein phosphatase 2A (PP2A) was also implicated in binding to Chk2 (Dozier et al., 2004) and, probably, in phospho-Thr68 dephosphorylation (Liang et al., 2006) . It is not surprising that more than one phosphatase is involved in Chk2 regulation. Further experimental work will be required to understand how the action of Wip1 and PP2A is coordinated with Chk2 regulation.
Wip1 expression accelerates the G2 checkpoint exit of cells subjected to ionizing IR We evaluated the role of Wip1 on Chk2-dependent DNA damage checkpoints using HCT15/HA-Chk2 cells and its parental Chk2-defective HCT15 cell line. We found that HCT15/HA-Chk2 cells exited from an IRinduced G2 arrest 2 h later than parental HCT15 cells that lack functional Chk2, and this additional delay was Wip1 phosphatase antagonizes Chk2 activation M Oliva-Trastoy et al abolished by increasing the expression of Wip1 in the HCT15/HA-Chk2 cells. These observations are consistent with Wip1 antagonizing the ability of Chk2 to maintain a G2 arrest induced by IR, as we expected from our biochemical analyses of the effect of Wip1 on Chk2 activation in response to IR. Increased Wip1 also accelerated the G2 exit of the parental HCT15 cell line by 0.5 h. This modest effect suggests that Wip1 can target checkpoint components other than Chk2 that also contribute to the G2 arrest of the HCT15 cells. Nevertheless, both cell lines show an initial robust G2 arrest in response to IR even when expressing elevated Wip1. Several studies have shown that Chk1 and Chk2 are partially redundant kinases that have similar effector targets . Recently, Donehower and colleagues showed that Wip1 can bind Chk1 and inhibit its kinase activity by dephosphorylation of the ATR-targeted Ser345 (Lu et al., 2005) . Using a U2OS cell model containing a stably integrated doxycyclineinducible (tet on) Wip1 transgene, they showed that increased Wip1 expression increased the percentage of cells that entered mitosis after g or UV IR, although it was not clear which Wip1 targets were responsible for this effect. Our results showing an accelerated G2 exit of irradiated HCT15/HA-Chk2 cells overexpressing Wip1 are consistent with the increased mitotic index of U2OS cells overexpressing Wip1. However, in order to determine the contribution of Chk1 to the IR-induced arrest of our HCT15 cells, we treated the cells with Chk1 siRNA before X-IR. Strikingly, Chk1 knock-down dramatically reduced the G2 arrest by 12 h. This result is consistent with previous work indicating that Chk1 has a stronger effect on blocking cell cycle progression in response to DNA damage compared to Chk2 (Zhao et al., 2002; Bartek and Lukas, 2003; Xiao et al., 2003) . The modest acceleration of the G2 exit of HCT15 cells by increased Wip1 is thus not consistent with a strong inhibition of Chk1 kinase activity in these cells. We note that Wip1 appears to be overexpressed to much higher levels in the tet-on U2OS cells used by Donehower and colleagues compared to the levels that we obtained by nucleofection of Wip1 expression plasmids in HCT15 cells. It is possible that Wip1 inhibition of Chk1 requires higher levels of expression than we achieved in our cell lines.
Wip1 and tumorigenesis
Early in tumorigenesis, before malignant conversion and probably as soon as overstimulations by growth factors take place, human cells constitutively activate the DNA damage response pathways. This cellular response is thought to be due to DNA replicative stresses and subsequent DNA damage that lead to activation of ATM, 53BP1, Chk2, p53, and probably ATR and Chk1 as well (Bartkova et al., 2005; Gorgoulis et al., 2005) . Activation of the DNA damage checkpoints induces cell cycle arrest and/or apoptosis, thereby constraining tumour progression. Events compromising the ATM-Chk2-p53 pathway contribute to genomic instability and tumour progression. In addition, Wip1-overexpressing tumours are aggressive and display a poor prognosis (Hirasawa et al., 2003) , whereas Wip1 À/À mice are resistant to spontaneous tumours, probably owing to an increased stress response activation upon DNA damage (Nannenga et al., 2006) . Thus, our results suggest that tumours overexpressing Wip1 are likely to evolve rapidly towards more advanced stages through a Wip1-dependent reduction of Chk2 activation.
In summary, we show that the Wip1 phosphatase can efficiently dephosphorylate phospho-Thr68 of Chk2 and thereby antagonize its activation by the ATM/ATR kinases in response to genotoxic stress. We show that this regulation can accelerate the rate at which cells exit G2 after ionizing IR. However, Wip1 is clearly not a global anti-ATM/ATR phosphatase, and its expression in physiological conditions cannot abrogate the DNA damage checkpoints. Rather, we propose that Wip1 has a regulatory role in stimulating the recovery from DNA damage. This downregulation of DNA damage checkpoints is likely to contribute to the oncogenic effect of Wip1 overexpression.
Materials and methods
Mammalian cell culture and treatments
The CHO cell line was from the American Tissue Culture Collection, and was transfected using Lipofectamine 2000 reagent (Invitrogen, San Diego, CA, USA). The human colorectal tumour HCT15 cell lines, stably expressing or not endogenous levels of HA-Chk2, were kindly provided by Dr Junjie Chen (Wu and Chen, 2003) ; they were transfected using the Amaxa nucleofection technology according to the manufacturer's instructions and allowed to recover 3 days before additional treatments. Irradiations were performed at a dose rate of 1 Gy/min using an X-ray Faxitron generator.
Plasmids, siRNA, antibodies and extract preparation pGEX-Wip1 expressing a GST-Wip1 fusion protein under an inducible promoter in E. coli, and pCMV-Wip1 constitutively expressing a Wip1-flag protein in mammalian cells were kindly provided by Dr Appella (Fiscella et al., 1997) . pGEX-PP2Ca was kindly provided by Dr Solomon (Yale University) and pGEX-Cdc25C by Dr Piwnica-Worms (Schwarz et al., 2003) . The following plasmids were constructed: pDEST20-Wip1 (expression of GST-Wip1 in insect cells by baculovirus infection); pDEST51-Wip1 and pDEST51-Wip1-Dead (expression in mammalian cells of Wip1-V5-His protein and its phosphatase dead counterpart (D314A), under the EF-1a promoter).
A siRNA directed against Wip1 was synthesized by (Qiagen, Courtaboeuf, France) and had the following sequence: 5 0 -GCCAGAACUUCCCAAGGAATT-3 0 . The plasmid pKDChk1-v1 (Upstate, Guyancourt, France) was used to knockdown Chk1 expression.
The following antibodies were used according to the manufacturer's instructions: rabbit polyclonal anti-phosphoChk2 Ser19, Ser33/35, Thr68, Thr387, Thr432 and Ser516 (Cell Signalling Technology, Danvers, MA, USA); rabbit polyclonal anti-Chk2 #07-057 (Upstate); mouse monoclonal anti-HA 16B12 (BabCO, Berkeley, CA, USA); rabbit polyclonal anti-Wip1 H-300 (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Whole-cell lysates (WCLs) were obtained from supernatants of cells lysed on ice with Complete HDN buffer (N-2-hydroxyl piperazine-N 0 -2-ehane sulphonic acid 20 mM, dithiothreitol (DTT) 1 mM, Igepal CA-630 0.5%, protease inhibitor cocktail (Roche, Meylan, France), phosphatase inhibitor cocktail 1 (Sigma, Lyon, France).
Purification of proteins GST-Wip1, GST-PP2Ca, and GST were produced in E. coli. GST-Wip1 was also expressed in High Five insect cells using the Bac-to-Bac Baculovirus Expression System (Invitrogen). Recombinant proteins were purified by binding to glutathione-sepharose 4B beads (Amersham Biosciences, Saclay, France).
Determination of the phosphatase activity of GST-Wip1 and GST-PP2Ca Casein was phosphorylated by either p38a or PKA (both from Upstate) with 20 mCi of (g-32 P)ATP in TMKD buffer (Tris HCl 40 mM, KCl 20 mM, MgCl 2 30 mM, DTT 2 mM, pH 8). Upon heat inactivation of the kinases and purification on MicroSpin G-50 Columns (Amersham Biosciences), the radiolabelled casein was used for dephosphorylation experiments in TMKD buffer in the presence of insect cells expressed GST-Wip1 or E. coli expressed GST-PP2Ca. Aliquots of the reactions were stopped by addition of 500 ml of TCA 5%. Time course reactions were filtered on Qiagen Nitrocellulose 0.45 mm HA filters, washed with TCA 5% and the remaining radioactivity was counted by liquid scintillation.
In vitro phosphatase assays Forty micrograms of WCL from CHO cells expressing HAChk2 were incubated in TMKD buffer, at 301C, for 10-40 min, with 10, 50 or 500 ng of insect cells expressed GST-Wip1, 80 or 800 ng of E. coli expressed GST-PP2Ca or 8 units of calf intestine phosphatase (CIP) (New England Biolabs, Ipswich, MA, USA). Reactions were stopped by addition of Laemmli buffer. Upon sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), blots were probed with the appropriated anti-phospho-Chk2 or anti-HA antibodies.
In vitro kinase assay To determine the Chk2 kinase activity in HCT15/HA-Chk2 and in transfected CHO cell extracts (200 and 40 mg, respectively), HA-Chk2 was immunoprecipitated using the HA Isolation Kit (Miltenyi Biotec, Paris, France) following the manufacturer's instructions (except immunoprecipitated buffer: Complete HDN, 300 mM NaCl; wash buffer: Complete HDN, NaCl 1 M). Then, columns were washed three times with 400 ml TMKD buffer preheated at 301C, 25 ml of preheated kinase assay mixture was added to each column (TMKD, ATP 50 mM, 10 mCi (g-32 P)ATP, 3 mg GST-Cdc25C) and the kinase assay proceeded at 301C for 1 h. HA-Chk2 and GST-Cdc25C were eluted with 1 Â sample buffer. Proteins were separated by SDS-PAGE, stained with Coomassie blue, and the gel was dried before quantification of the radioactivity with PhosphorImager (Molecular Dynamics, Saclay, France).
In vitro interaction test and GST-pull down GST fusion proteins were immobilized on glutathionesepharose 4B beads. Fifty microlitres of beads were incubated in HDN buffer for 2 h at 41C with 1 mg ml À1 bovine serum albumin and 1 mg of Chk2-His (kindly provided by Dr AlphaBazin, CEA/Marcoule), or with 150 mg of WCL from CHO cells transiently expressing HA-Chk2. The beads were then washed twice with HDN buffer complemented with NaCl or Igepal CA-630. The proteins were eluted with 1 Â Laemmli and analysed by Western blot. For the inverse pulldown assay, 200 mg of WCL from HCT15 cells stably expressing HA-Chk2 were incubated with 275 ng of GST-Wip1 for 30 min at 301C in TMKD buffer; HA-Chk2 was then immunoprecipitated, and the presence of GST-Wip1 was detected by Western blotting.
Cell cycle analyses
Cells were trypsinized, pelleted, washed twice with PBS and fixed in ethanol 70%. DNA staining was obtained with 50 mg/ ml propidium iodide in PBS in the presence of 100 mg/ml RNase. Analyses were performed using a FACScan (Becton Dickinson, Le-Pont-De-Claix, France and CellQuest software (Le-Pont-De-Claix, France).
